Difference between revisions of "Relugolix (Orgovyx)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(added package insert)
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist.  Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels.  There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.<ref>[https://www.myovant.com/our-science/relugolix/ Relugolix manufacturer's website]</ref>
+
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist.  Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels.  There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.<ref>[https://www.orgovyx.com/ Relugolix manufacturer's website]</ref><ref>[https://www.myovant.com/wp-content/uploads/2020/12/NDA-214621-Final-USPIandPI.pdf Relugolix (Orgovyx) package insert]</ref><ref>[[:File:Relugolix.pdf|Relugolix (Orgovyx) package insert (locally hosted backup)]]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a

Revision as of 04:54, 23 November 2021

General information

Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

History of changes in FDA indication

  • 12/18/2020: Approved for adult patients with advanced prostate cancer. (Based on HERO)

Also known as

  • Code name: TAK-385
  • Brand names: Orgovyx, Relumina

References